TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02518516
Drug: Rosuvastatin (≥10 mg)
Normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed \>120 days of the index date (i.e. no exposure within 120 days of the index date).
Study: NCT02518516
Drug: Simvastatin (≥40 mg)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Study: NCT02518516
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Study: NCT02518516
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to pravastatin will be defined as a prescription for any dose of pravastatin (ATC C10AA03) dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Study: NCT02518516
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to lovastatin will be defined as a prescription for any dose of lovastatin (ATC C10AA02) dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Study: NCT02518516
Drug: Simvastatin (<40 mg)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Study: NCT03767335
Drug: MEN1611
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEN1611 oral dose administered twice daily for a continuous 28-day cycle
Study: NCT02053935
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject will receive a priming dose of dextrose 20% to increase their glucose concentration by 125 mg/dl in the first 15 minutes. Then they will receive variable rates of dextrose 20% infusion to maintain glucose level at 180-220 mg/dl. Then, dopamine (200mg/250ml) will be titrated up to 5 mcg/kg/min with care not to increase blood pressure greater than 160 systolic. Dopamine will be infused for 3 hours.
Study: NCT02116608
Drug: Hydrocortisone Butyrate Cream, 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
Study: NCT03151408
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule
Study: NCT00679601
Drug: AN2690
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2690 7.5% Solution, once daily for 28 days
Study: NCT02887456
Drug: Endodontic treatment using Vitapex
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endodontic treatment using Vitapex
Study: NCT02887456
Drug: Endodontic treatment using MTA paste
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endodontic treatment using MTA paste
Study: NCT03058094
Drug: AC0010
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg, orally, BID
Study: NCT00003960
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01489631
Drug: sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sufentanil 1mcg/ml
Study: NCT00467935
Drug: intravitreal injection Lucentis (ranibizumab)
Normalized name: Lucentis Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravitreal injection Lucentis (ranibizumab)
Study: NCT00019864
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00019864
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00019864
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01212588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets once daily for seven days
Study: NCT00879957
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin will be added to PICC infusions at a dose of 0.5 units heparin per milliliter of intravenous fluid/parenteral nutrition.
Study: NCT00879957
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the no heparin group, the subjects will not receive heparin as an additive to their PICC infusions.
Study: NCT00742469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03327792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01173081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching dose of 20mcg of placebo once daily for 16 weeks or until study endpoint is achieved
Study: NCT01356966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo pills PO BID for12 weeks
Study: NCT03898583
Drug: Microarray patch A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microarray patch
Study: NCT03898583
Drug: Microarray patch B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microarray patch
Study: NCT03898583
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microarray patch vehicle
Study: NCT03898583
Drug: Daivobet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daivobet Gel
Study: NCT04178980
Drug: Simvastatin in relapsing remitting multiple sclerosis
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin use as adjuvant thearapy in relapsing remitting multiple sclerosis
Study: NCT01015833
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01671280
Drug: Azithromycin IV
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy.
Study: NCT02863055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered twice daily
Study: NCT03062423
Drug: Sofodelevier
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet contains 400 mg sofosbuvir
Study: NCT03686969
Drug: Octanorm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octanorm 0.5g/kg/week
Study: NCT02344225
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose)
Study: NCT02344225
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days
Study: NCT02344225
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days
Study: NCT01154647
Drug: 1 ml 0.9 % NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT03611426
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline solution
Study: NCT02182349
Drug: [14C]-BI 201335 NA radiolabelled drug
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03913819
Drug: First line treatment: oral NSAID and anticholinergic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral NSAID and anticholinergic agents
Study: NCT03913819
Drug: Second line treatment: additional treatment for pain control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin, tramadol, Lyrica
Study: NCT03913819
Drug: Third line treatment: A course of intravesical hyaluronate will be given.
Approvals — FDA: no, EMA: no, PMDA: no
Description: A course of intravesical hyaluronate will be given.
Study: NCT03269214
Drug: Topical Phenytoin 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received topical Phenytoin 5%+ Tetracycline after necrotic bone debridement .
Study: NCT01688024
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02668146
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered to study subjects
Study: NCT03312517
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive placebo.
Study: NCT04357457
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose 5% during 5 days
Study: NCT00093873
Drug: Anti-angiogenesis
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-angiogenesis
Study: NCT01231555
Drug: GSK2248761 100 mg once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1x100 mg capsule plus matching placebo
Study: NCT03509220
Drug: PBK-1701TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will receive PBK-1701TC for colonoscopy.
Study: NCT03509220
Drug: Standard oral preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will receive the standard oral preparation for colonoscopy
Study: NCT00054665
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m\^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
Study: NCT00054665
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m\^2 day IV day 5 bolus. Repeat cycle every 21 days.
Study: NCT00405444
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose of fentanyl that each child will receive will be 2 mcg/kg based on the child's weight. The medication will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
Study: NCT03233932
Drug: LeuplinⓡInj
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug(=LeuplinⓡInj)is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
Study: NCT05233657
Drug: JX11502MA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT00669617
Drug: Placebo to salbutamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to salbutamol delivered via MDDPI
Study: NCT00003632
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04737473
Drug: Opiod Free Anesthesia
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: The OFA protocol will entailed induction of anesthesia intravenously by the administration of the following drugs: magnesium sulfate 40mg/kg (without exceeding 2.5g), lidocaine 1.5mg/kg, ketamine 25mg, propofol 1.5-2mg/kg, dexamethasone 8mg and rocuronium
Study: NCT02723201
Drug: TAK-020 Captisol Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-020 solution.
Study: NCT02723201
Drug: TAK-020 SDT
Normalized name: Equisul SDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-020 Solid dispersion tablet.
Study: NCT02723201
Drug: TAK-020 IRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-020 immediate release tablet.
Study: NCT02723201
Drug: TAK-020 Solid Formulation
Normalized name: CORYDALIS SOLIDA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-020 solid formulation
Study: NCT01243112
Drug: 1% Lidocaine with Epinephrine (1:100,000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2ml Intradermal injection once.
Study: NCT01243112
Drug: 0.25% Bupivacaine with Epinephrine (1:200,000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2ml Intradermal injection once.
Study: NCT01243112
Drug: 1% Lidocaine, 0.5% Bupivacaine, and epinephrine (1:150,000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2ml Intradermal injection once.
Study: NCT01495247
Drug: BEZ235
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses of oral BEZ235 (BID), supplied as 50mg, 200mg, 300mg or 400mg in SDS sachets, together with standard weekly paclitaxel at a fixed dose (80mg/m²) during 1h by i.v. in infusion.
Study: NCT00375830
Drug: 99mTc-methyl diphosphonate
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiolabel for bone scan procedures
Study: NCT03200496
Drug: TALION®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug : Talion®
Study: NCT00010426
Drug: cysteamine hydrochloride
Normalized name: cysteamine hydrochloride
DrugBank: Cysteamine (DB00847)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01859377
Drug: V0498 - A mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oromucosal administration
Study: NCT01507363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for 7 days, starting on the day of surgery
Study: NCT00236366
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01859377
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single oral administration
Study: NCT03590912
Drug: Steroid Drug (prednisolone)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group will be treated with steroid drugs. Oral prednisolone, 1 mg/kg body weight daily in two divided dose for 1 week followed by half mg/kg/day in two divided dose for next one week.
Study: NCT01627587
Drug: GSK221149 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C: 100mg of GSK221149 single dose
Study: NCT01627587
Drug: GSK221149 750 mg + Food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment E: 750 mg of GSK221149 administered with a high fat meal
Study: NCT01448395
Drug: [14C]NXL104
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg/100mL intravenous solution
Study: NCT02085291
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine infusion to titrate MAP to usual level
Study: NCT03222427
Drug: [13C415N3] LY3314814
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an IV infusion
Study: NCT02222714
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, 0.9% sodium chloride in water, given as 100 mL IV infusion
Study: NCT02135835
Drug: Shenfu Zhusheye
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00858429
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 twice daily, for 14 consecutive days followed by a 7 day treatment free rest period for cycles 1, 2 and 3.
Study: NCT01988103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet BID for 16 weeks
Study: NCT01114529
Drug: Prograf or Neoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active CNI-based control (Prograf or Neoral)
Study: NCT00592475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT00440726
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2/day IV over 15 minutes on Day 1
Study: NCT00440726
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intrathecally to all patients who are CNS 1 at study entry on Day 15 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age
Study: NCT03634475
Drug: PP-001
Normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug - no placebo
Study: NCT02040506
Drug: IGN523
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravenously every week for 8 weeks. Dosing beyond 8 weeks will be permitted for subjects meeting criteria for ongoing clinical benefit and acceptable safety.
Study: NCT01442259
Drug: AFQ056
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01648257
Drug: GSK1265744 Na Salt Tablets
Normalized name: ibuprofen, sodium salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each tablet contains 30 mg of GSK1265744 sodium salt and excipients.
Study: NCT01535079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration
Study: NCT01535079
Drug: Ibuprofen 35 mg
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single administration
Study: NCT01535079
Drug: Ibuprofen 25 mg
Normalized name: diphenhydramine-ibuprofen 25 mg-200 mg oral capsule
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single administration
Study: NCT01535079
Drug: Ibuprofen 15 mg
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single administration
Study: NCT01181479
Drug: AG200-15 (cycles 1-13)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG200-15 containing ethinyl estradiol and levonorgestrel
Study: NCT00019071
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00143572
Drug: Magnesium Pidolate, Hydroxyurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Description: Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months. Mg pidolate will be given at an initial dose of 0.6 mEq/kg/day divided into 2 daily doses for the first cohort of patients. This dose will be escalated for the subsequent patient cohorts as defined by a classic Phase I design (according to toxicity).
Study: NCT01560702
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-30 cc of 1/10000 diluted epinephrine will be injected at edges of an actively bleeding ulcer.
Study: NCT04625972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (× 2 IM injections) of saline placebo on Day 1.
Study: NCT04483037
Drug: Bowklean
Approvals — FDA: no, EMA: no, PMDA: no
Description: assigned intervention
Study: NCT01245062
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEK inhibitor
Study: NCT01245062
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator Choice of DTIC or paclitaxel
Study: NCT03208452
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
Study: NCT03362593
Drug: MEDI7219
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Drug
Study: NCT03362593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02940132
Drug: SC10914
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC10914 will be administered orally.
Study: NCT01269333
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for 7 days
Study: NCT00448032
Drug: PPM-204
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02482155
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 400 mg single dose oral solution
Study: NCT04471337
Drug: BAY1817080
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY1817080 will be administered orally as tablet.
Study: NCT04359511
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: hémisuccinate d'hydrocortisone 3,5 mg/kg/jour (IV)
Study: NCT00599417
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo controlled
Study: NCT00616629
Drug: AZD1305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT01653119
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both of the two groups will be given standard ACS treatment according to treatment guidelines during the following 1 year.